Cargando…

Efficacy of a Selective Binder of α(V)β(3) Integrin Linked to the Tyrosine Kinase Inhibitor Sunitinib in Ovarian Carcinoma Preclinical Models

Ovarian carcinoma, the most lethal gynecological cancer, is characterized by late diagnosis, with drug resistance limiting the efficacy of platinum-based therapy. Since some integrins are upregulated in cancer, including ovarian carcinoma, they represent a potential target for drug delivery. Recepto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sartori, Andrea, Corno, Cristina, De Cesare, Michelandrea, Scanziani, Eugenio, Minoli, Lucia, Battistini, Lucia, Zanardi, Franca, Perego, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521192/ https://www.ncbi.nlm.nih.gov/pubmed/31013908 http://dx.doi.org/10.3390/cancers11040531

Ejemplares similares

Nintedanib-Containing Dual Conjugates Targeting α(V)β(6) Integrin and Tyrosine Kinase Receptors as Potential Antifibrotic Agents
por: Bugatti, Kelly, et al.
Publicado: (2022)

The Tyrosine Kinase Inhibitor Sunitinib Affects Ovulation but Not Ovarian Reserve in Mouse: A Preclinical Study
por: Bernard, Valérie, et al.
Publicado: (2016)

New Developments of the Principle of Vinylogy as Applied to π-Extended Enolate-Type Donor Systems
por: Curti, Claudio, et al.
Publicado: (2020)

New 4-Aminoproline-Based Small Molecule Cyclopeptidomimetics as Potential Modulators of α(4)β(1) Integrin
por: Sartori, Andrea, et al.
Publicado: (2021)

Nintedanib-αVβ6 Integrin Ligand Conjugates Reduce TGFβ-Induced EMT in Human Non-Small Cell Lung Cancer
por: Andreucci, Elena, et al.
Publicado: (2023)

Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer
por: Brooks, Colin, et al.
Publicado: (2012)

Multiplex staining depicts the immune infiltrate in colitis-induced colon cancer model
por: Pivetta, Eliana, et al.
Publicado: (2019)

Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis
por: Hu, Jialiang, et al.
Publicado: (2019)

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
por: Gotink, Kristy J., et al.
Publicado: (2015)

Novel Polymyxin-Inspired Peptidomimetics Targeting the SARS-CoV-2 Spike:hACE2 Interface
por: Bugatti, Kelly, et al.
Publicado: (2023)

Effective Antiviral Activity of the Tyrosine Kinase Inhibitor Sunitinib Malate against Zika Virus
por: Lin, Chen-Sheng, et al.
Publicado: (2021)

IL-1R8 Downregulation and Concomitant TLR7 and TLR9 Upregulation Are Related to the Pathogenesis of Canine Diffuse Large B-Cell Lymphoma
por: Riva, Federica, et al.
Publicado: (2022)

Retraction Note: Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis
por: Hu, Jialiang, et al.
Publicado: (2020)

Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence
por: Kloth, Jacqueline S. L., et al.
Publicado: (2015)

Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib
por: Huang, Qiang, et al.
Publicado: (2015)

Cranial Spinal Spreading of Canine Brain Gliomas after Hypofractionated Volumetric-Modulated Arc Radiotherapy and Concomitant Temozolomide Chemotherapy: A Four-Case Report
por: Urso, Gaetano, et al.
Publicado: (2022)

A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib
por: Henderson, Valerie C, et al.
Publicado: (2015)

Downregulation of miR-146a Contributes to Cardiac Dysfunction Induced by the Tyrosine Kinase Inhibitor Sunitinib
por: Shen, Li, et al.
Publicado: (2019)

Cardiac Metabolic Deregulation Induced by the Tyrosine Kinase Receptor Inhibitor Sunitinib is rescued by Endothelin Receptor Antagonism
por: Sourdon, Joevin, et al.
Publicado: (2017)

High efficacy of CpG-ODN, Cetuximab and Cisplatin combination for very advanced ovarian xenograft tumors
por: Sommariva, Michele, et al.
Publicado: (2013)

Receptor Tyrosine Kinase Inhibitor Sunitinib as Novel Immunotherapy to Inhibit Myeloid-Derived Suppressor Cells for Treatment of Endometriosis
por: He, Ying, et al.
Publicado: (2021)

Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials
por: Kim, Sungkyoung, et al.
Publicado: (2014)

Therapeutic efficacy of Sunitinib and other broad spectrum receptor tyrosine kinase inhibitors (RTKI) in bleomycin-induced pulmonary fibrosis
por: Knoerzer, D, et al.
Publicado: (2013)

When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report
por: Sbitti, Yassir, et al.
Publicado: (2018)

Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?
por: Ucar, Gokhan, et al.
Publicado: (2020)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

Metastatic Perivascular Epithelioid Cell Tumor Of The Kidney: A Case Report With Emphasis On Response To The Tyrosine-Kinase Inhibitor Sunitinib
por: AlAzab, Rami S, et al.
Publicado: (2019)

Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings
por: Wilson, S, et al.
Publicado: (2015)

Beta 2 integrin-dependent protein tyrosine phosphorylation and activation of the FGR protein tyrosine kinase in human neutrophils
Publicado: (1994)

Stable interaction between α5β1 integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1
por: Cascone, Ilaria, et al.
Publicado: (2005)

Osteonecrosis of the jaws produced by sunitinib: A systematic review
por: Vallina, Carmen, et al.
Publicado: (2019)

Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer
por: Alifrangis, C, et al.
Publicado: (2016)

Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors
Publicado: (1996)

Integrin Ligation Results in Nephrin Tyrosine Phosphorylation In Vitro
por: Verma, Rakesh, et al.
Publicado: (2016)

Non-Targeted Metabolomics Analysis of the Effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Heart, Muscle, Liver and Serum Metabolism In Vivo
por: Jensen, Brian C., et al.
Publicado: (2017)

Senescent Thyrocytes, Similarly to Thyroid Tumor Cells, Elicit M2-like Macrophage Polarization In Vivo
por: Mazzoni, Mara, et al.
Publicado: (2021)

Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer
por: Saronni, Davide, et al.
Publicado: (2022)

Preclinical evaluation of Sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastases
por: Schem, Christian, et al.
Publicado: (2013)

Modulation of immune cell infiltrate with sunitinib to improve anti-PD1 therapy in preclinical tumor model
por: Rayman, Patricia, et al.
Publicado: (2015)

Protein tyrosine phosphatase-1B regulates the tyrosine phosphorylation of the adapter Grb2-associated binder 1 (Gab1) in the retina
por: Rajala, Ammaji, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_k5ikl6qa3r32i5h0h8ihc0qf12